On December 27, 2023, Applied Molecular Transport Inc. (?AMTI?), completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023 (the ?Merger Agreement?), by and among Cyclo Therapeutics, Inc. (?Cyclo?), Cameo Merger Sub, Inc. and wholly owned subsidiary of Cyclo (?Merger Sub?) and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the ?Merger?). As of the Effective Time: Shawn Cross, a former director of AMTI, was appointed to the board of directors of Cyclo.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.51 USD | +2.72% | +19.84% | -5.03% |
May. 01 | HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target | MT |
Mar. 18 | Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.03% | 43.36M | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- CYTH Stock
- News Cyclo Therapeutics, Inc.
- Cyclo Therapeutics, Inc. Appoints Shawn Cross to the Board of Directors